Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study

Griffiths, 1978, Surgical resection of tumor bulk in the primary treatment of ovarian cancer, Natl Cancer Inst Monogr, 42, 131

Alberts, 1996, Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer, N Engl J Med, 335, 1950, 10.1056/NEJM199612263352603

Makar, 1995, The Prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer, Gynecol Oncol, 56, 175, 10.1006/gyno.1995.1027

Eisenkop, 1992, The impact of subspecialty training on the management of advanced ovarian cancer, Gynecol Oncol, 47, 203, 10.1016/0090-8258(92)90107-T

Le, 1997, Does debulking surgery improve survival in biologically aggressive ovarian cancer, Gynecol Oncol, 67, 208, 10.1006/gyno.1997.4839

Omura, 1989, Randomized trial of cyclophosphamide plus cisplatin with or without doxirubicin in ovarian carcinoma, J Clin Oncol, 7, 457, 10.1200/JCO.1989.7.4.457

Eisenkop, 1998, Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer, Gynecol Oncol, 69, 103, 10.1006/gyno.1998.4955

Bristow, 2002, Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era, J Clin Oncol, 20, 1248, 10.1200/JCO.20.5.1248

Heintz, 1986, Cytoreductive surgery in ovarian carcinoma, Obstet Gynecol, 67, 783, 10.1097/00006250-198606000-00007

Covens, 2000, A critique of surgical cytoreduction in advanced ovarian cancer, Gynecol Oncol, 78, 269, 10.1006/gyno.2000.5926

Hoskins, 1992, The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer, Gynecol Oncol, 47, 167, 10.1016/0090-8258(92)90100-W

Potter, 1992, Primary surgical therapy for ovarian cancer, Gynecol Oncol, 40, 195, 10.1016/0090-8258(90)90277-R

Jaeger, 2001, The effect of bowel resection on survival in advanced epithelial ovarian cancer, Gynecol Oncol, 83, 286, 10.1006/gyno.2001.6375

Eisenkop, 2001, The clinical significance of occult macroscopically positive retroperitoneal nodes in patients with epithelial ovarian cancer, Gynecol Oncol, 82, 143, 10.1006/gyno.2001.6232

Eisenkop, 2001, Procedures required to accomplish complete cytoreduction for ovarian cancer. Is there a correlation with “biological aggressiveness” and survival, Gynecol Oncol, 82, 435, 10.1006/gyno.2001.6313

Montz, 1989, Resection of diaphragmatic peritoneum and muscle, Gynecol Oncol, 35, 338, 10.1016/0090-8258(89)90074-7

Eisenkop, 1993, Peritoneal implant elimination during cytoreductive surgery for ovarian cancer, Gynecol Oncol, 51, 224, 10.1006/gyno.1993.1277

Bristow, 2001, Complete surgical cytoreduction for advanced ovarian carcinoma using the Argon Beam Coagulator, Gynecol Oncol, 83, 39, 10.1006/gyno.2001.6344

Eisenkop, 1991, Modified posterior exenteration for ovarian cancer, Obstet Gynecol, 78, 879

Rose, 1992, The cavitronal ultrasonic surgical aspirator for cytoreduction in advanced ovarian cancer, Am J Obstet Gynecol, 166, 843, 10.1016/0002-9378(92)91345-B

Deppe, 1988, Debulking surgery for ovarian cancer with the Cavitron Ultrasonic Surgical Aspirator (CUSA)—a preliminary report, Gynecol Oncol, 31, 223, 10.1016/0090-8258(88)90298-3

Spirtos, 1995, Cytoreductive surgery in advanced epithelial cancer of the ovary, Gynecol Oncol, 56, 345, 10.1006/gyno.1995.1061

Benedetti-Panici, 1991, Technique and feasibility of radical para-aortic and pelvic lymphadenectomy for gynecologic malignancies, Int J Gynecol Cancer, 133, 1

Eisenkop, 2001, What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer, Gynecol Oncol, 82, 489, 10.1006/gyno.2001.6312

Hacker, 1983, Primary cytoreductive surgery for ovarian cancer, Obstet Gynecol, 61, 413

Farias-Eisner, 1994, The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery, Gynecol Oncol, 55, 108, 10.1006/gyno.1994.1257

Chi, 2001, Identification of prognostic factors in advanced ovarian carcinoma, Gynecol Oncol, 82, 532, 10.1006/gyno.2001.6328

Naik, 2000, Complete cytoreduction, Gynecol Oncol, 78, 176, 10.1006/gyno.2000.5842

Prefontaine, 1994, Reproducibility of tumor measurements in ovarian cancer, Gynecol Oncol, 66, 87, 10.1006/gyno.1994.1253